[November 27, 2015] |
|
Research and Markets: Brain Ischemia - Pipeline Review, H2 2015
Research and Markets (http://www.researchandmarkets.com/research/rj9bd8/brain_ischemia)
has announced the addition of the "Brain
Ischemia - Pipeline Review, H2 2015" report to their offering.
The report, Brain Ischemia - Pipeline Review, H2 2015, provides an
overview of the Brain Ischemia's therapeutic pipeline.
This report provides comprehensive information on the therapeutic
development for Brain Ischemia, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Brain Ischemia and special features on late-stage and discontinued
projects.
Key Topics Covered:
-
Snapshot of the global therapeutic landscape of Brain Ischemia
-
Key pipeline products under drug profile section which includes
product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
-
Key players involved in the therapeutics development for Brain
Ischemia and enlists all their majr and minor projects
-
All dormant and discontinued pipeline projects
-
Brain Ischemia products under development by companies and
universities/research institutes based on information derived from
company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
Detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Brain Ischemia pipeline on the basis of target, MoA,
route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Benefits of this Report:
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Brain Ischemia
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Brain Ischemia pipeline depth and focus of Indication therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
CohBar Inc.
-
Immune Pharmaceuticals Inc.
-
Lixte Biotechnology Holdings, Inc.
-
NeuroNascent, Inc.
-
NeurOp, Inc
-
Prolong Pharmaceuticals
-
Spectrum (News - Alert) Pharmaceuticals, Inc.
-
Sylentis S.A.
-
The International Biotechnology Center (IBC) Generium
-
Vect-Horus S.A.S
For more information visit http://www.researchandmarkets.com/research/rj9bd8/brain_ischemia
View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005400/en/
[ Back To TMCnet.com's Homepage ]
|